Figure 1.
Summary of the study design.
Table 1.
Models used in the study for HIV-infected individuals who initiated HAART 1 January 1998 or thereafter, and within 6 months of that date had an undetectable VL (<50 copies/ml).
Table 2.
Characteristics of HIV-infected individuals initiating HAART after 1 January 1998 with a VL < 50 copies/ml within 180 days of HAART initiation.
Table 3.
Mortality rate ratio (MRR) of HIV-infected individuals initiating HAART after 1 January 1998 with a VL <50 copies/ml within 180 days of HAART initiation with censoring of individuals with virological failure (VL >500copies/ml) comparing time on statin with time not on statin.
Table 4.
Mortality rate ratio (MRR) of HIV-infected individuals initiating HAART after 1 January 1998 with a VL <50copies/ml within 180 days of HAART initiation, with no censoring due to virological failure, comparing time on statin with time not on statin.